Valuation: Fate Therapeutics, Inc.

Market Cap 286M 248M 231M 212M 401M 27.26B 407M 2.72B 1.07B 13.57B 1.07B 1.05B 45.51B P/E 2026 *
-2.26x
P/E 2027 * -2.38x
Enterprise Value 286M 248M 231M 212M 401M 27.26B 407M 2.72B 1.07B 13.57B 1.07B 1.05B 45.51B EV / Sales 2026 *
54.4x
EV / Sales 2027 * 54.5x
Free-Float
98.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.39%
1 week+1.66%
1 month-16.10%
3 months+60.13%
6 months+99.19%
Current year+149.34%
1 week 2.25
Extreme 2.25
2.56
1 month 2.25
Extreme 2.25
3.23
Current year 0.97
Extreme 0.97
3.23
1 year 0.91
Extreme 0.91
3.23
3 years 0.66
Extreme 0.6611
8.83
5 years 0.66
Extreme 0.6611
97.43
10 years 0.66
Extreme 0.6611
121.16
Manager TitleAgeSince
Chief Executive Officer 49 2024-12-31
Director of Finance/CFO 47 2025-10-19
Chief Operating Officer - 2021-06-30
Director TitleAgeSince
Chairman 78 2011-11-30
Director/Board Member 70 2014-03-16
Director/Board Member 47 2018-07-30
Date Insider Type Main position Quantity % Market Cap.
6/12/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
5/20/26 Sell

Compliance Officer

-25,590 0.0220%
4/20/26
Redmile Group LLC
OthersCompany 25,870,456 22.2516%
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%+1.66%+128.97%-34.84% 286M
+2.35%+2.74%+38.10%+74.02% 56.54B
-2.68%-6.51%+25.66%+62.29% 53.6B
+0.67%+1.40%-15.61%-13.72% 22.91B
-0.17%-7.78%-9.28%+352.92% 21.37B
+0.15%+0.36%+24.28%-14.44% 20.27B
-1.60%-2.28%+31.86%-29.13% 17.56B
-1.45%-7.15%+17.96%+554.50% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
+0.58%-4.23%+42.32%+160.72% 13.33B
Average -0.36%-3.25%+44.71%+140.01% 23.41B
Weighted average by Cap. +0.01%-2.95%+30.30%+120.23%

Financials

2026 *2027 *
Net sales 5.25M 4.56M 4.25M 3.9M 7.36M 501M 7.48M 50.05M 19.64M 249M 19.71M 19.27M 836M 5.24M 4.55M 4.24M 3.89M 7.35M 500M 7.46M 49.94M 19.6M 249M 19.67M 19.23M 834M
Net income -133M -115M -107M -98.54M -186M -12.66B -189M -1.27B -497M -6.3B -498M -487M -21.14B -148M -129M -120M -110M -208M -14.12B -211M -1.41B -554M -7.03B -556M -543M -23.58B
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
26-08-03 US$2.415 -1.43% 158,883
26-07-31 US$2.450 -2.39% 1,459,168
26-07-30 US$2.510 +6.36% 1,698,291
26-07-29 US$2.360 +1.72% 1,075,505
26-07-28 US$2.320 -4.53% 1,851,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2.450USD
Average target price
5.411USD
Spread / Average Target
+120.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock